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Summary 
Most laboratory strains  of mice have between two and eight endogenous superantigens. These 
viral superantigens (vSAGs) are coded by genes in the 3' long terminal repeats of endogenous 
mammary tumor viruses (Mtv's). A line of Mtv-negative mice and several lines of  mice contain- 
ing single Mtv's were created by inbreeding the  F2 progeny of CBA/CaJ  and  C58/J  mice, 
which have no Mtv integrants in common. This allowed the T  cell repertoire of H-2  k mice, 
unaffected by Mtv superantigens,  as well as the effects of vSAGs upon that repertoire, to be 
studied. Although each individual mouse had a different mix of C58/J and CBA/CaJ back- 
ground genes, the T  cell repertoires of different Mtv-negative mice were very similar and were 
reproducible. Since the background genes did not affect the V[3 repertoire, there are no super- 
antigens, other than those encoded by Mtv's,  that differ between CBA/CaJ and C58/J.  CD4 
and CD8 T  cells had quite different repertoires in the Mtv-negafive mice because of the effects 
of class I and class II major histocompatibility complex molecules on positive and negative se- 
lection,  vSAG3 was  found to  delete V[35 T  cells,  while  vSAG8  deleted V[37 T  cells,  and 
vSAG9 deleted V[313 T  cells in addition to their previously reported specificities,  vSAG17 de- 
letes a small proportion ofCD4 + T cells bearing V[311 and -12. vSAG14 and -30 have httle ef- 
fect on the T  cell repertoire and are not expressed in thymocytes and splenocytes. An endoge- 
nous superantigen that has a low avidity for a particular V[3 may positively select thymocytes, 
leading to an increased frequency of  peripheral T cells bearing the relevant V[3s. We found ev- 
idence that vSAG11 may positively select T  cells bearing V[38.2. Our data, which analyzed the 
effects of seven endogenous Mtv's,  showed little evidence of positive selection by any other 
vSAGs on T  cells bearing any V[3 tested, despite published reports to the contrary. 
M 
ls gene products can stimulate T  cells (1) because of 
.the ability of the superantigens encoded by Mls-like 
genes to stimulate and/or delete T  cells bearing certain V[3 
chains in their cx/[3 TCRs (2, 3). The known viral superan- 
tigens  (vSAGs) 1 in  mice  are  encoded in  the  3'  LTR  of 
mammary tumor viruses (MTVs) (4-7). These MTVs exist 
both as replicating virions, passed from mother to pup in 
the  milk,  and  as  endogenous  chromosomal  integrants, 
which  are  inherited  genetically.  There  are  at  least  30 
known endogenous MTVs, distributed among the various 
mouse strains and wild mice. 
1Abbreviations used in this  paper: MTV, mammary  tumor virus; RT, reverse 
transcfiptase; vSAG,  viral superantigen. 
The specificities of these vSAGs have been demonstrated 
by their ability to stimulate T  cells or by their ability to de- 
lete T  cells bearing certain V[3s in mouse strains containing 
the superantigen genes compared with strains  that do not. 
The difficulty with this analysis has been that almost all pre- 
senting  cells  and  mouse  strains  contain  several Mtv  inte- 
grants, and the effects of particular superantigens cannot be 
unambiguously separated from those of other superantigens 
present in the same cell line or mouse. In addition, the ef- 
fects of the H-2 haplotype on the T  cell repertoire and on 
the vSAGs make interpretation of differences difficult. 
To circumvent these problems, a line of mice was cre- 
ated that was free of Mtv's.  Although two strains  of mice 
free of Mtv's have been previously described, neither con- 
tained  a  well-known  MHC  haplotype  (8,  9).  Simulta- 
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and single Mtv integrants were produced. This was accom- 
plished  by  crossing  two  strains  of H-2~expressing  mice 
that do not have any Mtv integrants in common, CBA/CaJ 
and  C58/J,  and selectively breeding their progeny. These 
studies allowed an assessment of the T  cell V[3 repertoire in 
the  absence  of vSAGs  and  a  search  for  superantigenlike 
proteins  other  than  vSAGs  that  differ  between  the  two 
strains. 
Comparison of the single-Mtv mouse lines with the Mtv- 
negative lines allowed the evaluation of the effects of each 
vSAG on positive and negative selection.  In general,  only 
thymocytes  that  recognize  antigen  in  the  context  of the 
MHC  molecules  found in  the  thymic  epithelia  are  posi- 
tively selected  for maturation,  survival,  and  export  to the 
periphery  (10-13).  However,  developing thymocytes that 
recognize self-antigens bound to MHC molecules are elim- 
inated by a process called negative selection  (2,  3,  14-18). 
The  "thymic paradox"  is that thymocytes must recognize 
self-MHC  to survive but are eliminated  if they recognize 
self-MHC  plus  self-peptide.  The  avidity  hypothesis  ex- 
plains  this  paradox by stating  that  thymocytes with  a low 
but perceptible avidity for self-peptide/MHC are positively 
selected,  while  thymocytes with  a  higher  avidity for self- 
peptide/MHC  are  deleted  (19,  20).  Recent  experiments 
using  fetal  thymus  organ  culture  support  this  hypothesis 
(21-23).  If the  avidity hypothesis  is  correct,  a  vSAG  ex- 
pressed in the thymic epithelium that had a very low avid- 
ity for a particular TCR  V[3  element would allow T  cells 
bearing that V[3 element to be positively selected,  and the 
frequency  of peripheral  T  cells  bearing  that  V]3  element 
would increase. When we compared the V~ frequencies of 
eight single-Mtv mice with those of Mtv-negative mice, we 
found  evidence  of such  positive  selection  by  only  one 
vSAG. 
Materials and Methods 
Mice.  C58/J,  CBA/CaJ, AKR/J, and C57BL/6J mice were 
obtained  from  The  Jackson  Laboratory  (Bar  Harbor,  ME). 
Crosses  between  mice were  performed  in  the  National Jewish 
Center animal care facility (Denver, CO). 
Southern Blots.  Genomic DNA was prepared  from mouse tails 
by proteinase  K  digestion  (0.8 mg/ml in 5% SDS,  pH 7.5)  and 
was  digested  with  either  NcoI or BstXI,  subjected to  electro- 
phoresis  on 0.75%  agarose  gels, and transferred  to nylon filters 
(Genescreen;  DuPont, Wilmington, DE) using blotting apparatus 
(VacuGene XL; Pharmacia Biotech,  Inc., Piscataway,  NJ).  The 
filters  were  probed  with  an  EcoRI-BamHI  fragment  of the 
MTV(C3H)  LTR  cloned  into  pTZ18R-orfl  (24). The  probe 
was labeled  with 32p by random priming (Random Primers  Kit; 
GIBCO BRL,  Gaithersburg,  MD),  and hybridized at  65~  in 
500 mM phosphate buffer,  pH 7.2, 7% SDS. The filters received 
two  final washes  with  1%  SDS,  40 mM phosphate  buffer,  and 
were exposed for 1-7 d on x=ray film (XR; Eastman Kodak Co., 
Rochester, NY). 
Antibody Staining and Flow Cytometry.  Nylon wool-purified T 
cells from lymph nodes were analyzed for the expression  of vari- 
ous mouse V[3s with the following mAbs: anti=V[32, B20.6 (25); 
anti-VI33,  KJ25a  (26); anti-V~4  (PharMingen,  San Diego, CA); 
anti-V~5.1, MR9-4 (27); anti-V~5.1  and -V~5.2, MR9-4 (27); 
anti-V[36,  RR4-7  (28);  anti-V~7  (PharMingen);  anti-V~8.2, 
F23.2 (29); anti-V[38.1 and -V[38.2, KJ16 (30); anti-VI38.1, -V[38.2, 
and  -V~8.3,  F23.1  (29);  anti-V[39,  MR10-2  (31); anti-V[310 
(PharMingen);  anti-V]311,  RR3-15  (32); anti-V]312  (PharMin- 
gen);  anti-V~13  (PharMingen);  anti-V[314.  14-2 (33); and anti- 
TCR[3  H57-597  (34).  Cells  were  incubated  with  one  of the 
above-mentioned biotinylated mAbs, washed,  and stained  with 
streptavidin-coupled  PE  and  either  fluoresceinated  anti-CD4 
(GK1.5)  or anti-CD8 (2.43) as previously described  (35). At least 
15,000 cells were analyzed on a FACScan  |  (Becton Dickinson & 
Co., Mountain View, CA). The frequency ofV~5.2, V~8.1, and 
V~8.3 T  cells was calculated  by subtraction.  The anti-V[35 anti- 
body was  of variable  quality,  and the  calculated  frequencies  of 
V~5.2 T cells have a large variance  and unusual distribution. 
PCR Amplification, Cloning, and Sequencing of vsag30.  Genomic 
murine DNA digested with NcoI or PvulI was separated  on aga- 
rose  gels  as  described  above and purified  by GeneClean  (BIO 
101, Inc., Vista, CA) from the agarose cut out of the appropriate 
region as determined by Southern blot analysis, as previously de- 
scribed  (35). The vsag gene was amplified  by PCR with primers 
specific  for most of the  vsag's. The  5'  sense  oligo was  GGG- 
AATTCTCGAGATGCCGCGCCTGCAG, and the 3' antisense 
oligo was GGGGATCCTCTAGAGGGAACCGCAAGGTTGGG, 
complementary to a sequence outside the coding region. 
The PCR product was cut with EcoRl and BamHl. The 1-kb 
band was size separated  and purified by agarose gel electrophore- 
sis and GeneClean, and then cloned into PTZ 18R and sequenced 
by the chain termination method (36) using Sequenase  (United 
States Biochemical Corp., Cleveland,  OH). 
Reverse Transaiptase (RT)-PCR.  RNA was prepared from sple- 
nocytes and thymocytes by lysis and precipitation in 3 M  LiC1/6 
M urea. The RNA was then resuspended  in 10 mM Tris, pH 8.0, 
5 mM EDTA,  1% SDS,  and was phenol/chloroform, and then 
chloroform extracted,  followed by ethanol precipitation.  Resid- 
ual DNA was digested  by incubating for 10 rain at 37~  with 5 
U  of RNase-free DNase I (Boehringer Mannheim Corp., India- 
napolis,  IN), followed by phenol/chloroform extraction,  cDNA 
was made from 2 p,g of total RNA using the superscript  RT and 
random hexarners  (GIBCO BRL). vsag transcripts were amplified 
by 35 cycles of  PCR (95~  for I rain, 55~  for I rain, 72~  for 1 
rain)  using pan-vsag-specific primers.  The 5' primer was GGG- 
AATTCTCGAGATGCCGCGCCTGCAG, and the  3'  primer 
was ACACCAAGGAGGTCTAGC. 
Statistics.  All results are shown as the average value  of all the 
mice tested  +  SEM. The deletion significance levels (P) were cal- 
culated  using the one-tailed Student's t test. After correcting the 
nondeleted V[5 frequencies  for the deletions  (see below), a two- 
tailed  t test was used to determine the significance of any further 
positive  or negative V~ skewing.  A P value  <0.003 was required 
for significance, since 16 tests were performed on each mouse line 
(5% +  16 =  0.003). 
Frequency Conrction  for T Cells Bearing Nondeleted V~s.  To normal- 
ize  the  frequency of T  cells bearing undeleted  V~s,  these  fre= 
quencies  must  be  multiplied  by the  ratio  of the  frequency of 
T cells bearing these V~s in Mtv-negative  mice/the frequency of 
T cells bearing these V~s in a single-Mtv mouse line. Since V~I, 
-15, and -16 could not be directly measured,  two separate meth- 
ods  of normalization were used.  The first method included the 
estimated  frequency of V~I, -15, and -16 by subtracting  the fre- 
quencies  of measured V[Ss from 100%. However, if there was ev= 
idence of deletion among VI31, -15, or -16, then a second calcu- 
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directly measured and not deleted.  For example,  in Mtv8 mice, 
V135.1, -5.2, -7, and -11 and 12 CD4 + T cells are deleted and ac- 
count for 6.0% ofCD4  + T cells, while they account for 23.9% of 
CD4 + T cells in Mtv-negative mice. By the first method, the cor- 
rection factor is (100  -  23.9)/(100  -  6.0)  =  0.810.  However, 
after correcting, it is clear that at least one of the untested VI3 is 
being deleted.  Therefore, these  VI3s are  not used in the second 
method, and the correction factor adds the frequencies  of T cells 
beating the undeleted  V~2, -3, -4, -6, -8.1, -8.2, -8.3, -9, -10, - 13, 
and-14 =  (53.4/73.4)  =  0.728. 
Results 
CBA/CaJ mice contain Mtv8, -9, and -14, while C58/J 
mice contain Mtv3, -7, -17, and -30 (37).  Since these two 
strains, both of which are H-2  k, have no Mtv's in common, 
we were able to create a line of mice that had no Mtv's by 
crossing the  two  strains.  422  (CBA/CaJ  ￿  C58/J)F2  ani- 
mals were tested by Southern blot analysis for the presence 
of these and any other Mtv's. No other Mtv's were seen, al- 
though  the  probe,  the  complete  1-kb  LTR  from MTV- 
(C3H),  should  bind  to  all  Mtv's  still  containing  an  LTR 
(37). Mtv3, -7, -8, -9,  - 14, and -17 segregated as expected 
for a single genetic locus for each virus, with 75% of the F2 
progeny containing one or two copies of the virus  (Table 
1).  However,  93.9%  of  the  F  2  progeny  contained  the 
Mtv30 band, indicating that two separate genetic loci were 
responsible for the band (Table 1). 
Mtv30, like most Mtv's, was originally characterized as a 
unique  band  on  an  EcoRI  Southern  blot  probed  with 
MTV LTR.  It was mapped to chromosome 12 in AKR/J 
mice, but it did not map to chromosome 12 in C57BL/6J 
or  NZB/B1NJ  mice  (38).  Two  back-cross  experiments 
were conducted to verify the existence of two distinct inte- 
gration  sites,  using  CBA/CaJ  mice  that  do  not  contain 
Mtv30. (CBA/CaJ ￿  AKR/J)F1 mice were back-crossed to 
CBA/CaJ  to  determine  if more  than  one  integration  site 
existed  for Mtv30 in  AKR/J  mice.  50%  of CBA/CaJ  ￿ 
(CBA/CaJ  ￿  AKR/J)F1  mice  would  be  expected  to  be 
Mtv30  + if there  was  one  integrant,  but  75%  would  be 
Mtv30  + if there were two integrants.  Since only 25% were 
positive (Table 2), it is likely that only one integration site 
in AKR/J mice exists.  CBA/CaJ  ￿  (C57BL/6J  ￿  AKR/ 
J)F 1 mice  were  screened  to  determine  if C57BL/6  and 
AKR  mice  contained  the  same Mtv30 integration  site.  If 
this were the case, then the  (C57BL/6J  ￿  AKR/J)F 1 par- 
ents would be homozygous for the Mtv30 integration,  and 
their progeny would all contain one copy of Mtv30.  Since 
only 16 of 20 progeny were Mtv30  +, according to South- 
ern blot analysis (Table 2), the Mtv30 integrants in C57BL/ 
6J and AKR/J mice are unlinked, and there are two differ- 
ent integration sites  for Mtv's that nevertheless have identi- 
cal DNA band sizes after digestion with EcoRI (38), NcoI, 
PvulI, BstXI, BsmI, and ScaI (data not shown). 
The Sequence ofvSAG30.  Genomic DNA from AKR/ 
J, C57BL/6J, and RF/J mice was digested with EcoRI and 
separated  by  agarose  gel  electrophoresis.  DNA  from  the 
12-30-kb region, where Mtv30 is found, was cut out, iso- 
lated,  and  amplified by PCR  using pan-vSAG-specific 5' 
and 3' primers.  PCR products were cloned into pTZ (35). 
Clones from all of the mice had the same sequence (Fig. 1), 
even though AKR/J and C57BL/6J mice have two distinct 
Mtv30  proviruses  with  unlinked  integration  sites.  The 
amino acid sequence of vSAG30 is most closely related to 
that ofvSAG9 (Fig. 1), from which it differs by 14 residues. 
Perhaps surprisingly, most of these differences are not clus- 
tered at the carboxy-terminal end of the protein,  the por- 
tion thought to confer VI3 specificity. If expressed, vSAG30 
might therefore share the specificities of vSAG9 for T  cells 
bearing V135.1,  -5.2, -11, and -12. 
Generation of the Mtv-negative and Single-Mtv  Mouse Lines. 
Five  of the  (CBA/CaJ  ￿  C58/J)F2  mice  that  contained 
three or four Mtv's each were selected for further breeding. 
An Mtv-negative mouse line was produced by the pathway 
illustrated  in  Fig.  2.  Seven  other  lines  were  also  created, 
each  containing a  single Mtv.  Southern  blots from repre- 
sentative mice in each line are shown in Fig. 3. The single- 
Mtv mouse lines are heterozygous for their respective Mtv 
integrants at the moment; however,  homozygous lines are 
being generated.  Later, descendants of 129/J class I knock- 
Table 1.  Frequency  of Restriction Enzyme Fragments Characterizing Various Mtv's in 422 (CBA/CaJ ￿  C58/J)F  2 Mice 
Mtv DNA  Frequency of  P (X  2 test of  P (X  2 test of 
fragment  Chromosome  F  e mice positive  one gene)  two genes) 
3  11  0.755  >0.75  <0.005 
7  1  0.782  >0.1  <0.005 
8  6  0.749  >0.9  <0.005 
9  12  0.766  >0.5  <0.005 
14  4  0.746  >0.75  <0.005 
17  4  0.771  >0.25  <0.005 
30  12  0.939  >0.005*  <0.95 
*X  2 = 68.4. 
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Characterizing Mtv3 0 in CBA/Ca.] Back-  Cross Progeny 
No. Mtv 30 
Back-cross  positive/total  Frequency 
CBA/CaJ X (CBA/CaJ X AKR/J) F  1  4/16  0.25 
CBA/CaJ X (C57BL/6J X AKR/J)F~  16/20  0.80 
out mice (1~2  m-) were bred to introduce other Mtv's. (129/ 
J  [~2m-  x  B10.BR./J)F2  mice  that  were  I-A  b-,  I-E  k+, 
[52m-  (35) were back-crossed to the Mtv-negative mice for 
three  generations.  This  resulted  in  a  line  of Mtv11  mice 
that were H-2  k/k, [32m  + 
Mtv Expression.  The  level  of expression  of individual 
vsag's has been difficult to determine because of the  high 
degree of homology between them. To determine whether 
the  endogenous  vsag's are  expressed,  we prepared cDNA 
from total RNA prepared from splenocytes and thymocytes 
from individual mice of each of the single-Mtv mouse lines, 
and  from  several  Mtv-negative  mice.  Any  vsag genes 
present in the cDNA were amplified by PCR.,  using pan- 
vsag-specific  5' and 3' primers. 
vsag RNA from mice containing vsag3, -7, and -17 was 
expressed in the spleen and thymus (Fig.  4). vsag P,  NA was 
found in the spleen,  but not in thymocytes of mice con- 
taining vsag8 and -9. Even so, however, vsag8 and -9 might 
be expressed in the thymic epithelium or in cell types less 
frequent  in  the  thymus,  such  as  macrophages, B  cells,  or 
dendritic cells. Thymocytes and splenocytes from Mtv-neg- 
ative mice as well as Mtv14 and Mtv30 mice did not express 
detectable vsag transcripts. 
T Cell Repertoire of  Mtv-negative Mice.  The native T cell rep- 
ertoire of H-2  k mice, unaffected by Mtv superantigen selec- 
tion,  has not previously been determined.  The  TCR. V[3 
repertoire of lymph node T  cells from Mtv-negative  mice 
was  measured by flow  cytometry.  The  VI3  repertoire  of 
CD4 and CD8 T  cells was quite different (Fig.  5).  For ex- 
ample, 9% of CD8  T  cells,  but only 2% of CD4 T  cells, 
bore V135.1. Conversely, 8% ofCD4 T  cells, but only 1.5% 
ofCD8 T  cells, bore VI~12. Generally, VJ32, -5.1, -5.2, -6, 
-7, -8.1, -9, -11, -13, and -14 were more frequent on CD8 
T  cells, while VI33, -4, -8.2, -8.3, -10, and -12 were more 
frequent on CD4 T  cells.  This disparity implies that class I 
and class II MHC molecules tend to select T  cells bearing 
different sets of Vl3s, because of either negative or positive 
selection (35). 
The existence of a monovariate distribution  of VI3 fre- 
quencies and small standard  deviations from noninbred  F 6 
to F10 MW-negative mice from several different lines of de- 
scent (including several MW-negative siblings of the single- 
Mtv lines) imply that there are no additional superantigens 
encoded  by background genes  that  differ between  CBA/ 
CaJ and C58. 
Mtv14-, Mtvl7-, and Mtv30-expressing Mice.  T  cells from 
mice containing  only Mtv14,  Mtv17,  or Mtv30  (either or 
both genes) were analyzed for VI3 frequency and compared 
with  21  mice  containing  no  Mtv's  (Fig.  6  and  Table  3). 
These  previously uncharacterized  superantigens  had  only 
small effects on the T  cell repertoire.  Only VI3 frequency 
differences with a P value "<0.003 by the Student's t test are 
discussed. 
Mtv14  mice had a slight reduction  in  the  frequency of 
V132 CD4 but not CD8 T  cells by comparison with Mtv- 
negative animals.  The sequence  of vSAG14 has not been 
determined but may be similar to the exogenous MTVs pre- 
viously reported to react with T  cells bearing VI32 (39-41). 
vSAG30  is  very  similar  in  amino  acid  sequence  to 
vSAG9 (Fig.  1) and should therefore delete the same subset 
of T  cells  as vSAG9, i.e.,  those bearing V135.1, -5.2,  -11, 
and -12. However, vsag30 is not expressed or is only poorly 
1  10  2O  3O  4O 
Mtv30  ATGCcGCG~CTGCAGCAGAAATGG-rTG~ACT~C~GT~CTACACTTAGGA~CAAG~G~TTG-n-~C~CA~CAAGGACGA~Cc~C~T~C~ 
Mtv9  ...................................  OC  ...........................................................  C ...................... 
vSAG30  M  P  R  L  Q  Q  K  g  L  N  S  R  E  C  P  T  L  R  R  E  A  A  K  G  k  F  P  T  K  D  D  P  F  A  C  T  R  M  S  P 
vSAG9  ............  A  ...................  S  ....... 
SO  6O  70  80 
Mtv30  TCAGACAAAGACATACTCATTCTCTGCTGCAAACTTGGCAT/~CTCTGCTTTGCCTC~F~GCTAT~CGT~CC~MTA~ 
Mtv9  .......................................................................................................................  C 
vSAG30  S  D  K  D  I  L  I  L  C  C  K  L  G  I  A  L  L  C  L  G  L  L  G  E  V  A  V  R  A  R  R  A  L  T  L  D  S  F  N  S 
vSAG9  ..............  " .......................... 
90  100  110  120 
Mtv30  T~7`CTGTGCAACg~ACAATCTAAACAATT~C~ACT~GA~CTTCCT~CTGGGGCAAGGA~C~C~G~C`~ACT~C~A~G~c~~TA~TA 
Mtvg  ...............................................................................................  CT..  "A ................... 
vSAG30  S  S  V  Q  D  Y  N  L  N  N  S  E  N  S  T  F  L  L  G  Q  G  P  Q  P  T  S  S  Y  K  P  H  R  L  C  P  S  E  I  E  I 
vSAG9  ................................  F  Y  ...... 
130  140  150  160 
HTv30  AGAATGCTTGCTAA/~A~TATATTTTTACCAATAAGA~CAATCCAA~AGGT~ATTA~AA~CACTA~C~TAAGAAAT~T~AT  ~A~A~A~A~GG 
Mtv9  ................................................................  T  .............  G....G.  .,C  ............................  A.  ,. 
VSAG30  R  M  k  A  K  N  Y  I  F  T  N  K  T  N  P  I  G  R  L  L  I  T  H  L  R  N  l  S  L  S  f  S  T  I  r  T  Q  I  q  R 
vSAG9  ...........................  I  E  P  .......... 
llO  180  igO  200 
14tv30  TTAGAAAT~TAGAAAATAGA/U~`GAGACGCTCAACCTCAGT~CAGGTGCAAGGACTATCGGCCACA~~G~GCG~TA 
14tv9  .......................................  G  ..................................................  A.A .............  T ............. 
vSAG30  L  E  H  G  I  E  N  R  K  R  R  S  T  S  V  K  EQVQG k  S  A  T  G  L  E  V  l  E  G  K  R  S  A  F  V  ~  I 
vSAG9  .............  A  ................  K  ....  v  .... 
210  220  230  240 
Htv30  GGAGACAGGTGGTGC`CAACCAG~C~CTTATAGGAC.ACCTTACATCTACk~CC~AC~GATGCCCCGT~C~TATA~TAT~TA~T 
Ntv9  .................................  G .......................................................  C .........  A  .................... 
vS~30  G  O  R  W  W  Q  P  G  T  y  R  R  P  Y  I  Y  R  P  T  D  A  P  L  P  Y  T  G  R  Y  D  L  N  F  D  R  W  V  T  V  N 
VSAG9  ...........  G  .....................  N  ...... 
2S0  260  ZZ0  Z80 
Mcv30  GGCTATAAAGTGTTATACAGATCCO'CCCCTTTCGTGAAAGACr  CGCCAGAGCTAC,  ACCTC~GT~~C~T~A~T~AT 
Mtv9  ........................................................................................................................ 
vSAG30  G  Y  K  V  L  Y  R  S  L  P  F  R  E  R  L  A  R  A  R  P  P  W  C  V  L  T  Q  E  E  K  D  DM  KQQV  H  D  Y 
vSAG9  ........................................ 
￿9  29O  300  H0  320 
Mtv30  A~FATCTAAGAA~TAAACGlT~GGGGAAAGA~TTT~CA1TATACCAAGGACC~AGCAGTG~CTAGACTA~A~G~TA~T~AT~T~ 
Mtv9  .........  G ......  G. ￿9  -G  ...........  G ..........................  G .......................  T ..........................  T ......... 
vSAG30  I  Y  L  R  T  E  I  N  V  W  G  K  I  F  H  Y  T  K  E  G  A  V  A  R  L  L  E  H  I  S  A  O  T  F  G  M  S  Y  N  G 
vSAG9  ￿9  .  ￿9  G  -  G  M  ................................. 
Figure 1.  The DNA sequence and deduced amino 
acid sequence of vsag30 compared with vsag9. These 
data are available  fi:om  GenBank under accession num- 
ber Banklt17116 U37259. 
1496  Mtv-negative  and Single-Mtv Mice Figure 4.  Expression of vsag transcripts as shown by RT-PCR. cDNA 
from spleen and thymus of Mtv-negative  and single-Mtv mice was tested 
for the presence ofvsag transcripts by amphfying with primers specific for 
conserved regions of the 5' and 3' ends of  the vsag gene for 35 cycles. The 
790-bp band is the expected size of the amplified vsag gene, while  the 
~400-bp band is an artifact of the PCR that is not present when only 25 
cycles are used to amplify the vsag  gene. As a positive control for the qual- 
ity of the cDNA, the 13-actin gene was used. 
Figure 2.  A  hneage diagram showing the derivation of the Mtv-nega- 
tive and Mtv8 mouse lines. Each female or male mouse is divided into 
eight octants representing the eight Mtv provimses present in the parental 
strains. The octant is shaded black if the mouse is homozygous for the 
particular Mtv, gray if heterozygous, and white if negative. 
expressed (Fig. 4) and had only a slight reduction in the fre- 
quency of the VI3s not tested (VI31, -15, and -16) in CD4 
T  cells compared with Mtv-negative  mice. 
Mtvl 7 mice had significant decreases in VI311 and V[312 
CD4 T  cells  (Fig.  6 and Table 3). This deletion pattern is 
similar to that seen in Mtv8,  -9, and -11 mice, except that 
T  cells bearing Vl35.1 and -5.2 are unaffected (37). The de- 
letion is variable,  not occurring in  all  of the Mtv17  mice 
tested (data not shown). This superantigen protein may be 
poorly expressed, although we saw vsag-containing message 
in both splenocytes and thymocytes (Fig.  4). The deletions 
may be dependent on an environmental effect such as in- 
fection or stress,  leading to  vsag expression.  No  effect of 
Mtvl 7 upon T  cells bearing VI37 was seen, although the re- 
ported sequence of vsagl7  (42)  is similar to  that of V[37- 
deleting superantigen Mtv23  (35).  It is unlikely that Mtvl7 
encodes a  superantigen  that  is  specific for V[3s that  were 
not tested  (V[31, V[315,  or V[316),  because, if one of the 
untested Vl3s was  deleted, the percentage of T  cells unac- 
counted for by the tested V[3s should decrease, and it does 
not by any significant fraction (Fig. 6). 
vSAG3,  -7,  -8, and -9 Each Delete T  Cells Bearing One of 
Several  V~8  Chains.  vSAG7,  encoded by Mtv7  (formerly 
classified  as Mls-la)  has previously been reported to delete 
T  cells bearing V[36,  -7,  -8.1,  and -9  (2,  3,  43,  44).  The 
four Mtv7 mice tested did delete both  CD4  and  CD8  T 
Figure 3.  A  Southern blot of the various mouse lines. Genomic DNA 
from the parental strains, the Mtv-negative  mouse, and the seven single 
mouse hnes containing single-Mtv integrants was digested with Ncol and 
probed with MTV LTR. 
1497  Scherer et al. 
Figure 5.  The VI3 T  cell repertoire of Mtv-negative  mice. T  cells from 
lymph nodes of Mtv-negative  mice were  stained with biotinylated anti- 
bodies for the various V~s, as well as  CD4  and CD8,  and analyzed by 
FACScan  |  The data are presented as the percentage of CD4 or CD8 T 
cells that are positive for each V~. ( ~1  ), CD4 T  cells;  ( ['----7 ), CD8 T 
cells.  Each point  is  the  average  value of 21  mice  +  SEM.  Error  bars, 
where  not visible, are within the symbol. The frequency of other V~s 
(V~I,  V~15,  and V~16)  was  calculated for each mouse by subtracting 
from 100%  the frequencies of all the V~s tested. Figure 6.  The V[3 T cell  repertoire  ofMtvl4,  Mtv17, and Mtv30 mice. 
(A) CD4 or (/3) CD8 lymph  node T cells  from various mouse  lines were 
analyzed as in Fig. 4. (gT"/~),  Mtv-negative mice (n = 21); (O), Mtv14 
mice (n = 11); (I~), Mtv17 mice (n = 15); (A), Mtv30 mice (n = 16). 
cells bearing these VI3s and none of the other V[3s tested 
(Fig. 7 and Table 3), The efficiency of deletion of the vari- 
ous VI3s confirms the hypothesis that vSAG7 has the stron- 
gest  avidity for V136, followed by VI38.1  and  VI39,  and 
then V[37 (45). 
vSAG3, a member of the Mtvl, -3, -6, and -13 family of 
viral  superantigens,  has  been  reported  to  delete  T  cells 
bearing V133, and this is borne out in our mice (Fig. 7 and 
Table 3). However, vSAG3 also reacts with CD4 and CD8 
T  cells bearing V[35.1  and -5.2,  since many of these cells 
disappeared in Mtv3 mice. This is a novel finding but not 
entirely unexpected,  as vSAG6,  a  closely related protein, 
was previously reported to delete VI35-bearing T  cells (46). 
Since the carboxy-terminal 60 amino acids ofvSAG1, -3, -6, 
and -13 are almost identical, we would expect that vSAG1 
and vSAG13 would also induce deletion ofT cells bearing 
V135.1 and VI35.2.  vSAG3 also  induced deletion of about 
one-fourth of the CD4 T  cells bearing the Vl3s not tested 
(Vl3sl,  -15, and -16). 
Mtv8,  -9,  and  -11  have  related  sequences,  vSAG8, 
vSAG9,  and vSAGll  all  induce deletion of CD4  T  cells 
bearing V135.1, -5.2,  -11,  and  -12,  although  vSAG9  in- 
duces  the  most  complete  deletion  (Fig.  8  and  Table  3). 
However, the efficiencies of deletion of CD8 T  cells differ 
greatly between the three superantigens, probably because 
of better expression of vSAG9 rather than sequence differ- 
ences between the  superantigens,  vSAG9  deletes most  of 
the  CD8  T  cells  bearing  V[~5.1,  -5.2,  -11,  and  -12; 
vSAG11  deletes V[35.2-, V[311-,  and V[312-bearing CD8 
T  ceils;  while vSAG8 deletes only V[312-bearing CD8  T 
cells. The specificities ofvSAG8, -9, and -11 had some mi- 
nor differences with those previously reported (47).  In the 
previous paper, vSAG8 and -11 were thought not to delete 
V[35-bearing T  cells. This conclusion was probably reached 
because  CD4  and  CD8  T  cells  were not measured sepa- 
rately, and vSAG8 and -11 do not delete CD8 V[~5 T  cells 
eflqciently.  Since V~5  T  cells  are  overrepresented in  the 
CD8 population compared with the CD4 population, de- 
tection of the CD4 deletion might be hindered when total 
T  ceils are compared. 
Interestingly, vSAG8  also  deletes  CD4  T  cells  bearing 
V[37 (Fig.  8  and Table 3), while vSAG9 and -11  do not. 
This might be because of minor amino acid differences be- 
tween vSAG8 and -9 (see Discussion). In addition, vSAG9 
deletes about one-fourth of CD4 T  cells bearing V[313. 
Positive Selection by Mtv vSA Gs.  vSAGs are noted for their 
ability to induce deletion in the thymus of T  cells bearing 
particular V[3 chains.  However, they might also participate 
in  positive  selection.  We  investigated  this  possibihty  by 
comparing the  frequencies of TCR V[3s in  Mtv-negative 
and Mtv single-positive mice. In Mtv single-positive mice, 
the frequency of T  ceils bearing each nondeleted V~ is, of 
course,  increased.  To compare the  frequencies of T  cells 
bearing nondeleted VI3s with V[3 frequencies in Mtv-nega- 
tive mice, the frequencies must be normalized with a correc- 
tion factor that makes the total frequency ofT cells bearing 
nondeleted VI3s equal in both lines of mice (see Materials 
and Methods). 
The corrected V[3 T  cell repertoires for mice expressing 
single Mtv's are shown in Figs. 9 and 10. There is only one 
significant increase in V[3  frequency compared with Mtv- 
negative mice. Mtvl 1 mice have a 10% higher frequency of 
V~8.2 CD4 + T  cells (Fig.  10 and Table 3). This could be 
because of positive selection.  The increased frequency of 
V[38.2  CD4 T  cells was observed in two separate experi- 
ments. There were no other significant increases in V[3 fre- 
quency after correction for the deletions. 
The  corrected frequencies also  allowed a  more  careful 
study of  weak VI3-specific  deletions. If only a small propor- 
tion of T  cells bearing a particular V[$ are deleted (perhaps 
because of the ci or the D-  or J[3), the remaining T  cells 
bearing that VI3 will increase in frequency because of other 
deletions, masking the small deletion that takes place. This 
actually occurs with several vSAGs. 
Mtv7 and Mtv-negative  mice have identical frequencies 
of V[38.2  CD4  T  cells,  and  Mtv7  mice  actually  have  a 
higher frequency ofV[38.2 CD8 T  cells (Fig. 7). However, 
after correction for the other deletions caused by vSAG7, 
the frequency of V[38.2-bearing T  cells is reduced by 13% 
in Mtv7-expressing  mice  (Fig.  9  and Table 3).  This con- 
firms  earlier studies  showing that  vSAG7  could stimulate 
some but not most V~8.2 T  cell hybridomas (2, 48). Simi- 
larly,  after correction, Mtv9 and Mtv 11 mice have reduced 
frequencies ofCD8 T  cells bearing V[~13, while Mtv8 mice 
have  reduced frequencies of CD4  T  ceils  bearing V[313. 
1498  Mtv-negative and Single-Mtv Mice Table 3.  The Percentage of T  Cells Bearing Particular V~fls Deleted or Selected by Single Mtv in H-2  k Mice 
Percentage of CD4  Percentage of CD8 
Mtv  VIB  T  cells deleted  P*  T  cells deleted  P* 
Mtv3  VIB3  95%  < 10 -I6  89%  10 -9 
VIB5.1  82%  10- 9  95%  <  10-16 
VIB5.2  84%  <10 -1  81%  10 -1~ 
other  24%  0.0007  NS 
Mtv7  VIB6  93%  <10 -16  96%  10 -l~ 
VIB7  74%  10 -l~  66%  10 -8 
VIB8.1  82%  10-4  90%  10-s 
(V~8.2)  (13%)  (10 -s)  (14%)  (0.001) 
VIB9  82%  10-9  79%  10-4 
Mtv8  Vl35.1  66%  10-7  NS 
VIB5.2  75%  10 -4  NS 
Vl~7  61%  10 -4  NS 
VIB11  59%  0.001  NS 
VIB12  94%  10-13  65%  0.0003 
(VIB13)  (25%)  (10 -s)  NS 
(other)  (34%)  (0.0002)  NS 
Mtv9  VIB5.1  81%  10 -14  95%  <10 -16 
V[35.2  98%  <10 -16  95%  10 -1l 
VIBll  94%  <10 -16  68%  10 -5 
VIB12  98%  10 -16  96%  10 -9 
FIB13  25%  0.002  (17%)  (0.0001) 
(other)  (21%)  (0.002)  NS 
Mtv 11  VIB5.1  72%  10-12  NS 
V[~5.2  70%  10 -9  58%  10 -8 
(VIBS.  2)  (+ 10%)  (0.0006)  NS 
VIB11  96%  <10 -16  80%  10 -12 
VI312  98%  <10 -16  88%  10 -8 
(V[313)  NS  (21%)  (0.003) 
Mtv14  VIB2  9%  0.001  NS 
(VIBI 1)  (9%)  (0.003)  NS 
(other)  (15%)  (0.001)  NS 
Mtv17  VIB11  11%  0.002  NS 
VIB12  35%  0.0003  NS 
Mtv20  (VIB2)  (13%)  (0.001)  NS 
other  13%  0.002  NS 
Values in parentheses  are significant only after correcting for other deletions.  A +  before the percentage deleted indicates an increase in the percent- 
age ofT cells bearing that V~. 
* Probability  of no deletion as determined by Student's t test. 
NS, No significant deletion, P >0.003 by Student's t test. 
1499  Scherer et al. Figure 7.  The V[3 T cell repertoire of Mtv3 and Mtv7 mice. (A) CD4 
or (B) CD8 lymph node T cells from various mouse lines were analyzed 
as in Fig. 4. (~YT~), Mtv-negafive mice (n =  21); (C)), Mtv3 mice (n = 
7); ([]), Mtv7 mice (n = 4). 
Figure  8.  The V[3 T cell repertoire ofMtv8, Mtv9, and Mtv11 mice. 
(A) CD4 or (B) CD8 lymph node T cells from various mouse lines were 
analyzed as in Fig. 4.  ([~V~),  Mtv-negative mice (n =  21); (C)), Mtv8 
mice (n = 7); (V]), Mtv9nfice (n =  13); (A), Mtv11 mice (n = 8). 
These results and the previous observation that vSAG9 de- 
letes  CD4  T  cells bearing V[313  indicate  that vSAG8, -9, 
and -11 have a low avidity for V[313 that results in a partial 
deletion  of those  T  cells.  Mtv8  and  Mtv9  mice  also  have 
slightly reduced frequencies of "other" CD4 T  cells (V[31, 
-15,  and -16),  suggesting that one of these V[3s is also de- 
leted. Mtv14 mice also have reduced numbers ofV[311 and 
other CD4 T  cells after correction, while Mtv30 mice have 
a slight reduction in V[32-bearing CD4 + T  cells. 
Discussion 
Mtv30 Duplication  and Sequence.  We  have  shown  that 
there  are  two  unlinked  Mtv30  bands  in  C58/J  mice  and 
that  the  Mtv's  known  as  30  are  at  different  chromosomal 
locations  in  AKR/J  and  C57BL/6J  mice.  Therefore,  it  is 
probable that C58/J mice contain both the integrant found 
in AKtk/J  and the  integrant  in  C57BL/6J.  Since  the  two 
integrants  are  unlinked,  it  should  be  possible  to  separate 
them  on  a  Southern  blot  using  an  appropriate  restriction 
enzyme.  However,  we  could not separate  the  two Mtv30 
integrants  using six enzymes: EcoRI, PvulI,  NcoI, BstXI, 
ScaI, or BsmI, even though ScaI and BsmI cut within  the 
Mtv30 LTR  (data  not shown).  This  could be  explained  if 
the  predecessor virus of Mtv30 integrated  in a  region of a 
chromosome that was subsequently duplicated.  If the flank- 
ing regions were also duplicated,  the size of the bands con- 
taining the LTR would always be the same. 
The sequence of vSAG30 is very similar to that of other 
members of the M/sf family, vSAG8, -9, and -11. Thus, we 
would expect it to have the specificity characteristic  of this 
family for  T  cells  beating  V[35,  -11,  and  -12.  However, 
vSAG30 does  not induce  any deletions,  probably because 
of poor or no expression, which could result from a defect 
in  the  promoter.  Another  hypothesis  is  that  the  whole 
chromosomal region where Mtv30 integrated has been shut 
off, e.g.,  by excess methylation or centromeric  proximity. 
If it is a region of chromosomal duplication, this might pre- 
vent  deleterious  effects  of increased  gene  dosage  to  the 
mouse. 
Specificity of vSA G8,  -9, and -11.  The M/sf family, which 
includes Mtu8,  -9, and - 11, has a previously reported speci- 
ficity for T  cells  bearing V~5.1,  -5.2,  -11,  -12,  and -17a. 
Our results show that they also have a weak reactivity with 
T  cells  bearing  V~13  and  at  least  one  other  V~  among 
V~I, -15, and -16. This is probably V~16, as it is quite ho- 
mologous  to  V[311  and  -12.  Mtu17  also  belongs  in  this 
family by virtue of its specificity for T  cells  bearing VJ~I 1, 
and -12.  However,  the  published  sequence  of vSAGt7  is 
slightly different from vSAG8, -9, and -11  (42, 49) and ho- 
mologous to vSAG23, which is specific for VJ37  (35).  Al- 
though  vSAG23  only  stimulated  T  cell  hybrids  bearing 
VI37 (35), it is possible that it induces the deletion ofT cells 
1500  Mtv-negative  and Single-Mtv Mice Figure 9.  The nondeleted VI3 T cell repertoire ofMtv3, Mtv7, Mtv14, 
and Mtvl7 mice, corrected for the vSAG deletions. The V~3 T cell reper- 
toire of (,4) CD4 or (B) CD8 T cells from the various single-Mtv mouse 
lines in Figs. 6 and 7 was corrected for the V[3-specific  deletions induced 
by each superantigen to allow comparison of the nondeleted VI3 percent- 
ages with those of Mtv-negative mice. V[3s deleted in each mouse line and 
Mtv's with correction factor (c.f,) =  1.00 are not shown. The c.f. was the 
percentage of Vl3s not deleted by a particular vSAG in Mtv-negative 
mice/the percentage of  those same V~s in the single-Mtv mouse. ([~), 
Mtv-negative mice (c.f. =  1.00); (O), Mtv3 mice (c.f. =  0.80 CD4, 0.81 
CD8); (U]), Mtv7 mice (c.f. =  0.87 CD4, 0.75 CD8); (A), Mtv14 mice 
(c.f. =  0.96 CD4,  1.00 CDS); (V), Mtv17 mice (c.f. =  0.96 CD4,  1.00 
CD8). All data are presented as average ￿  c.s  -+ SEM X c.f. 
bearing  V[311  and  V[~12.  This  deletion  would  normally 
not  be  noticed,  because  all strains  containing Mtv23  also 
contain Mtv8. 
Why vSAG8 Deletes  V~7-bearing T  Cells.  vSAG8 deletes 
T  cells bearing V[37, while superantigens encoded by other 
members of the MI.4 family, Mtv9 and Mtv 11, do not. The 
only sequence difference in the carboxy-terminal polymor- 
phic region of these three superantigens is that vSAG8 has 
an  isoleucine  rather  than  a  methionine  at  position  273. 
vSAGs  contain  a  second  polymorphic  region  at  residues 
174-198, which was shown not be involved in vSAG7 and 
vSAG1  specificities for V[38.1  and V~33, respectively (50). 
It is noteworthy,  however,  that  the  V[37-reacting vSAGs: 
vSAG8, vSAG23, vSAG(M12), and vSAG(SHN), all con- 
tain a  glutamic  acid at residue  176,  an  arginine at  residue 
183, and a leucine at residue 197  (35, 51). It is our hypoth- 
esis that the first polymorphic region between residues 174 
and 198 contributes to specificity for V[37, while the speci- 
ficity for other V[3s  may be determined solely by the  car- 
boxy-terminal residues. The  first polymorphic region may 
have  a  purely negative contribution to binding, with  cer- 
Figure 10.  The nondeleted V~3 T  cell repertoire of Mtv8, Mtv9, and 
Mtvl I mice, corrected for the vSAG deletions. The V]3 T cell repertoire 
of (A) CD4 or (B) CD8 T cells from the various single-Mtv mouse lines 
in Fig. 8 was corrected for the VI3-specific  deletions as in Fig. 9. ( [7~ ), 
Mtv-negative mice (c.f. =  1.00); ((3), Mtv8 mice (c.f. =  0.73 CD4, 0.91 
CD8); ([-]), Mtv9 mice (c.f. =  0.74 CD4, 0.76 CD8); (A), Mtv11 mice 
(c.f. -- 0.81 CD4, 0.81 CD8). All data are presented as average ￿  c.s  + 
SEM ￿  c.s 
rain residues sterically hindering the association with VI37. 
vSAG7  and  other members  of the  Mls-1  family also react 
with  V[37.  However,  since  their  sequence  at  both  poly- 
morphic  regions is completely different from those  of the 
vSAGs discussed here, they probably bind VI37 in a  differ- 
ent way, such that their V[37 specificity is inseparable from 
that for V[36, -8.1, and -9. 
Positive  Selection by vSAGs.  Positive selection can be de- 
fined as the process that selects for survival T  cells that bear 
an avidity for self-MHC and foreign peptide. However, the 
thymocytes  actually  selected  are  only  exposed  to  self- 
MHC/self-peptide during the event. The avidity hypothe- 
sis states that T  cells with a low avidity for self-MHC/self- 
peptide  are  positively selected,  and  that  these  T  cells will 
cross-react with a high avidity for self-MHC and some for- 
eign peptide. If the avidity hypothesis of positive selection 
is correct, vSAGs might cause  the  overselection of T  cells 
bearing  V[3s  with  which  the  vSAGs  could  react  weakly. 
While there have been reports of possible positive selection 
by vSAGs  (52),  others have  not found  any  evidence  of it 
(53-56).  However,  any positive selection present in these 
systems could have been obscured by positive selective ef- 
fects that are ubiquitous to  all Mtv vSAGs or by the  dele- 
tions also occurring in most mice. 
1501  Scherer et al, We could examine the frequency of 16 different V[3s in 
the mice used in these experiments with a wide range of 
similarities  to  one another.  For example,  the  amino  acid 
residues ofV[312 are 68% identical to those of V~311, 23% 
identical  to  V[32,  and  intermediately identical  to  several 
other  V[3s. We  expected that  at  least  one  of these  V[3s 
would  have  a  low  enough  avidity for the  vSAGs  which 
recognize VJ312 well to be positively selected. We found 
that V~38.2 CD4 T cells seemed to be positively selected by 
vSAG11, vSAG8 also led to an increase in Vl38.2  CD4 T 
cells,  that was not significant after correction (P =  0.11). 
Therefore, we feel that vSAG8 may also slightly positively 
select VI38.2  T  cells,  but that this  selection is masked by 
our inability to correct for V[31 and VJ315, since no anti- 
body against  these V[3s is yet available.  Vl38.2  is  the  VI3 
most  homologous  to  V[37 (62%  amino  acid  homology). 
Since vSAG8 has a high enough avidity for VJ37 to induce 
deletion, it may have a lower avidity for V[38.2.  Similarly, 
vSAG11, which does not delete V[37, may have an  even 
lower avidity for V[38.2,  an avidity in the right range for 
positive selection to occur. 
Our results indicate that vSAG7 does not positively se- 
lect CD4 VI314 T cells (P =  0.08) or CD8 V~314 T cells (P = 
0.16),  an  observation which  contradicts previous findings 
that  vSAG7  positively selected  Vj314-bearing  T  cells  in 
several  strains  of mice,  including  some  that  shared  the 
MHC haplotype (H-2  k) used in our experiments (52). The 
most probable explanation for the disparity is that the in- 
creased selection was due to strain-specific effects. Another 
possible explanation for the difference is that several vSAGs 
somehow cooperate to  produce  specificities that  are  not 
present in the individual vSAGs. 
Although  eight vSAGs were investigated for effects on 
15 different V[3s, only one increase of V[3 usage was  seen 
that could be due to positive selection, and the affected V~3 
frequency rose by only 10%, after correcting for the other 
deletions.  Several theories can be put forward to  explain 
the  paucity of observed positive selection by the  vSAGs. 
The most interesting would be that thymocytes require an- 
other  signal  in  addition  to  low-avidity  binding  of their 
TCR to be positively selected. For example, ifa conforma- 
tional change in the TCR. is required for activation (57), 
this  change may preclude positive selection.  If vSAGs al- 
ways induce the conformational change, they would be in- 
capable of inducing positive selection. 
A  simpler explanation is that few of the other Vj3s are 
homologous at the vSAG-binding site,  even though there 
is  much  overall  sequence  homology.  Since  the  vSAG- 
binding site is  not yet known,  this  cannot be disproved. 
Similarly, most V[3s that bind with sufficient avidity to be 
positively selected may subsequently be negatively selected. 
This seems unlikely because of the large number of homol- 
ogous V]3s and vSAGs, some of  which should have interac- 
tions of low enough avidity to avoid deletion in the thy- 
mus.  However, a  low-avidity interaction between vSAG 
and V[3 might be influenced by D[3, J[3, or Vs. In this case, 
the  vSAG  might positively select some  T  cells  bearing a 
particular V[3 while having a high enough avidity to delete 
other T  cells  bearing the  same V~.  In such a  case,  there 
could be an increase, decrease, or no change in the V[3 fre- 
quency. Again, it seems unlikely that the frequencies of aI1 
V~s would remain unchanged. 
Some  aspect  of positive  selection  may  preclude  most 
vSAGs from selecting. An interesting possibility is that the 
vSAG-binding  site  on VJ3  TCR  is  occupied by another 
molecule during positive selection. This hypothetical mol- 
ecule, possibly a cellular SAG structurally related to super- 
antigens,  could be  an  avidity enhancer  molecule  present 
only in positively selecting cells (58) or present in all TCR- 
MHC  interactions  (59).  The  binding  of this  molecule 
would block only low-avidity interactions of the vSAG to 
nonoptimal V[3s but not the bigb-avidity interaction with 
the deleted Vl3s. Finally, ira particular ceil type such as cor- 
tical epithelial cells were responsible for positive selection 
in the  thymus in vivo,  the positively selecting cell might 
not express the vSAGs. 
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